Comparison of Survival in Primary and Repeat Heart Transplantation From 1987 Through 2004 in the United States

The Papworth Experience With the Levitronix CentriMag Ventricular Assist Device

“…Given the poor outcome of early heart re-transplantation, we use the CentriMag for continued support of the failing allograft until a period of neurologic assessment and hemodynamic stabilization is reached. 19,20 The patient who underwent repeat transplantation within 1 week was fortunate to receive another allograft that had been rejected previously from all other UK centers for various reasons. Without it, his chances of survival were very slim.…”

Incidence and outcome of Levitronix CentriMag support as rescue therapy for early cardiac allograft failure: a United Kingdom national study

“…Outcomes for patients bridged to acute retransplantation were poor; 40% died in hospital, 60% within the first year. In an era of severe donor heart shortage, this fuels the debate regarding organ allocation to such a high-risk group when other patients may gain a greater survival advantage from the same organ [16][17][18].…”

Outcomes and survival following heart retransplantation for cardiac allograft failure: a systematic review and meta-analysis

“…Several therapeutic interventions including aggressive immunosuppressive therapy, percutaneous transluminal coronary angioplasty, laser myocardial therapy, coronary artery bypass grafting, valvular repair and temporary and long term mechanical circulatory assist devices have been proposed; however, heart retransplantation (RTx) remains the only viable long-term treatment for end-stage cardiac allograft failure (4)(5)(6)(7)(8). Despite annual RTx rates of as high as 6% as reported by the 2017 ISHLT data (9), the literature on RTx is ambiguous with several studies reporting conflicting findings in regards to the survival and viability of this therapy (10,11).…”